Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Via Pharmaceuticals licenses drug candidates from Roche
January 2009
SHARING OPTIONS:

SAN FRANCISCO—Via Pharmaceuticals Inc., a cardiovascular disease-focused biotech, announced Dec. 23 it signed worldwide licensing agreements with Roche for two sets of compounds: the first, Roche's thyroid hormone receptor (THR) beta agonist, a clinically ready candidate for the control of cholesterol, triglyceride levels and potential in insulin sensitization/diabetes; and the second, multiple compounds from Roche's preclinical diacylglycerol acyl transferase 1 (DGAT1) metabolic disorders program. Under the terms of the agreements, Via will assume control of all development of the compounds, own exclusive worldwide rights for all potential indications and receive undisclosed milestone payments for development and royalties upon commercialization. DDN

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.